Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ONLY FOR CHILDREN<br />
PHARMACEUTICALS<br />
Institut Villemin<br />
10 avenue de Verdun<br />
75010 PARIS - FRANCE<br />
Phone: +33 1 57 27 86 87<br />
or +33 6 98 71 02 12<br />
Fax: +33 1 57 27 86 80<br />
Email: estelle.habert-ortoli@o4cp.com<br />
Web site: www.o4cp.com<br />
Contact: Estelle HABERT-ORTOLI<br />
Only for children pharmaceuticals ® (O4CP) is a <strong>French</strong> pharmaceutical company (SAS)<br />
founded in 2007 developing adapted medicines for children. The company addresses<br />
an important unmet medical need th<strong>at</strong> experts and regul<strong>at</strong>ory authorities have clearly<br />
identified: the need for adapted medicines for children. O4CP is active in Oncology,<br />
Immunology, Infectious Diseases and Neurology, and present in Europe (Paris, France)<br />
and United St<strong>at</strong>es. O4CP is developing a pipeline of 8 molecules.<br />
OROXCELL<br />
102 avenue Gaston Roussel<br />
Parc Biocitech<br />
93230 ROMAINVILLE - FRANCE<br />
Phone: +33 1 41 83 72 20<br />
Fax: +33 1 41 83 72 27<br />
Email: christophe.dini@oroxcell.com<br />
Web site: www.oroxcell.com<br />
Contact: Christophe DINI<br />
Oroxcell is pursuing drug research and development of NCEs in the indic<strong>at</strong>ion of Pain.<br />
Oroxcell is seeking a partner wishing to undertake the development and marketing of<br />
the safe and active NCEs.<br />
Besides, Oroxcell is a well-recognized CRO offering a unique one-stop-shopping<br />
pl<strong>at</strong>form to assess skin and oral absorption (ADME) and Toxicity profile form issued<br />
life sciences industry. Oroxcell is actively involved in setting up unique predictive<br />
altern<strong>at</strong>ive technologies to animal. Oroxcell is GLP compliant for both cosmetic and<br />
pharmaceutical activities.<br />
55
Change language